Johnson & Johnson has projected its lung cancer drug Rybrevant could achieve $5 billion in peak revenue. At the recent ASCO annual meeting, J&J executive Joshua Bauml explained his company’s strategy for this drug in lung cancer and beyond.
Johnson & Johnson subsidiary Janssen was awarded approval for Rybrevant, the latest in a string of decisions for targeted therapies for non-small cell lung cancer. Rybrevant is the first approved targeted therapy addressing a subset of patients whose disease is characterized by a particular mutation to cancer protein EGFR.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.